HK Stock Market Move | DUALITYBIO-B(09606) soars over 6% with expectations for intensive readout of clinical data in 2026.

DUALITYBIO-B (09606) rose over 6%, as of press time, up 6.04% to HK$340.6, with a turnover of HK$1.54 billion. On the news front, according to the medical cube, on January 26, the American clinical trial recruitment website showed that BioNTech has initiated the first Phase III clinical trial of BNT324 (DB-1311). This drug is the fifth B7-H3 ADC to enter Phase III. BNT324 is a B7-H3 ADC developed by Yimesin Bio, authorized to BioNTech in April 2023, giving the company rights for development, production, and commercialization outside of China. Guolian Minsheng Securities pointed out that the Phase III ADC+IO and core monotherapy clinical data will be concentrated in 2026. The three ADC pipelines jointly developed by Yimesin Bio and BioNTech are expected to read out multiple clinical data on combination IO dual antibodies in 2026. The firm believes that Yimesin Bio is leading the wave of ADC iterations and commercialization is expected in 2026. Yimesin Bio continues to develop next-generation novel ADCs, including dual antibody ADCs, novel mechanism payload ADCs, and self-rescuing ADCs. Two dual antibody ADCs have already entered clinical stages, and the ADC DB-1316 with a unique novel MOA payload is expected to address the issue of existing ADC resistance and is poised to enter clinical stages soon.